| Drug ID: | Drug49 |
|---|---|
| Drug Name: | Vancomycin |
| CID: | 14969 |
| DrugBank ID: | DB00512 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05376228, , NCT00355602, , NCT06582264, , NCT04968951, , NCT02765256, , NCT06794944, , NCT05370885, , NCT02618187, , NCT03759041 |
| Molecular Formula: | C66H75Cl2N9O24 |
| Molecular Weight: | 1449.2 g/mol |
| Isomeric SMILES: | C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H] |
| Synonyms: | VANCOMYCIN; 1404-90-6; Vancomicina; Vancomycine; Vancomycinum; vancomicin; HSDB 3262; Vancomycine [INN-French]; Vancomycinum [INN-Latin]; Vancomicina [INN-Spanish] |
| Phase 0: | 11 |
| Phase 1: | 47 |
| Phase 2: | 99 |
| Phase 3: | 97 |
| Phase 4: | 121 |
| Description: | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. [PubChem] |
Molecular Structure
No molecular structure data available
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt452 | 14969 | Vancomycin | 6610 | SMPD2 | Rattus norvegicus (Norway rat) | 30545405 | [ampicillin co-treated with neomycin co-treated with gentamicins co-treated with metronidazole co-treated with vancomycin] results in increased expression of SMPD2 protein |
| dt453 | 14969 | Vancomycin | 6611 | SMS | Mus musculus (house mouse) | 18930951 | Vancomycin results in increased expression of SMS mRNA |
| dt454 | 14969 | Vancomycin | 9304 | SNORD22 | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SNORD22 mRNA |
| dt455 | 14969 | Vancomycin | 6637 | SNRPG | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SNRPG mRNA |
| dt456 | 14969 | Vancomycin | 8835 | SOCS2 | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SOCS2 mRNA |
| dt457 | 14969 | Vancomycin | 6648 | SOD2 | Mus musculus (house mouse) | 18930951 | Vancomycin results in increased expression of SOD2 mRNA |
| dt458 | 14969 | Vancomycin | 6649 | SOD3 | Mus musculus (house mouse) | 18930951 | Vancomycin results in increased expression of SOD3 mRNA |
| dt459 | 14969 | Vancomycin | 6652 | SORD | Mus musculus (house mouse) | 18930951 | Vancomycin results in increased expression of SORD mRNA |
| dt460 | 14969 | Vancomycin | 6659 | SOX4 | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SOX4 mRNA |
| dt461 | 14969 | Vancomycin | 6678 | SPARC | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SPARC mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06582264 | A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis | PHASE1 | RECRUITING | Microbiotica Ltd | Ulcerative Colitis | BIOLOGICAL: MB310|OTHER: Placebo|DRUG: Vancomycin | Details |
| NCT04968951 | Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC) | EARLY_PHASE1 | TERMINATED | Ari M Grinspan | Ulcerative Colitis|FMT|Fecal Microbiota Transplant | DRUG: Metronidazole|DRUG: Placebo|DRUG: Vancomyci… | Details |
| NCT03759041 | A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis | PHASE2 | TERMINATED | Seres Therapeutics, Inc. | Ulcerative Colitis | DRUG: Vancomycin Pre-Treatment|DRUG: Placebo for … | Details |
| NCT02618187 | A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis | PHASE1 | COMPLETED | Seres Therapeutics, Inc. | Ulcerative Colitis | DRUG: SER-287|DRUG: Placebo|DRUG: Placebo Pre-Tre… | Details |
| NCT02765256 | Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease | PHASE2 | COMPLETED | University of Pennsylvania | Crohn's Disease | DRUG: Fluconazole|DRUG: Vancomycin|DRUG: Neomycin… | Details |
| NCT04014413 | Safety and Efficacy of Fecal Microbiota Transplantation | None | RECRUITING | Chinese University of Hong Kong | Crohn Disease|Ulcerative Colitis|Celiac Disease|I… | PROCEDURE: Fecal Microbiota Transplantation | Details |
| NCT05376228 | A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD | Not Available | UNKNOWN | University Hospital Birmingham NHS Foundation Trust | Inflammatory Bowel Diseases; Primary Sclerosing C… | DRUG: Oral Vancomycin | Details |
| CTIS2023-507425-42-00 | A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory Bowel Disease - VanC-IT | PHASE2 | Not Recruiting | University Of Milano Bicocca | Primary Sclerosing Cholangitis MedDRA version: 2… | Product Name: , Product Code:SCP32734155, Pharmac… | Details |
| NCT05876182 | A Prospective, Randomized, Placebo-controlled Clinical Trial of Oral Vancomycin in Adults and Young Adults (15-17 Years Old) Affected by Primary Sclerosing Cholangitis With or Without Inflammatory Bowel Disease | PHASE2 | Recruiting | University of Milano Bicocca | Primary Sclerosing Cholangitis;Liver and Intrahep… | Drug: Oral Vancomycin;Other: Placebo | Details |
| NCT06794944 | Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients with Inflammatory Bowel Disease | PHASE4 | NOT_YET_RECRUITING | Brigham and Women's Hospital | Inflammatory Bowel Disease (IBD)|Clostridioides D… | DRUG: Vancomycin (POC)|DRUG: Fidaxomicin | Details |
| EUCTR2022-000875-37-IT | A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory Bowel Disease - Vancomycin in Primary Sclerosing Cholangitis in Italy | PHASE2 | Not Recruiting | UNIVERSITÀ DEGLI STUDI MILANO BICOCCA | Primary Sclerosing Cholangitis MedDRA version: 2… | Trade Name: LEVOVANOX Product Name: LEVOVANOX Pro… | Details |
| NCT02464020 | A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis | PHASE1 | Not recruiting | University of Minnesota | Primary Sclerosing Cholangitis;Inflammatory Bowel… | Drug: Vancomycin | Details |
| NCT01918813 | None | Not Available | Not recruiting | Chikara Tashiro | Inflammatory Bowel Disease;Hepatobiliary Disease;… | Drug: vancomycin, mupirocin ointment | Details |
| NCT01802073 | Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects | PHASE3 | Not recruiting | Stanford University | Primary Sclerosing Cholangitis | Drug: Oral Vancomycin | Details |
| EUCTR2009-018034-11-SE | Open pilot study of treatment with vancomycin to children and adolescents with primary sclerosing cholangitis - vanco-psc | Not Available | Authorised | Karolinska Institutet | Primary Sclerosing Cholangitis (PSC) is a progres… | Trade Name: Vancomycin Product Name: vancomycin P… | Details |
| NCT05370885 | VE202 in Patients with Mild-to-Moderate Ulcerative Colitis | PHASE2 | RECRUITING | Vedanta Biosciences, Inc. | Ulcerative Colitis|Colitis, Ulcerative | BIOLOGICAL: VE202|DRUG: Vancomycin Oral Capsule|O… | Details |
| NCT00355602 | Antibiotics for the Treatment of Ulcerative Colitis | None | COMPLETED | University of Dundee | Colitis, Ulcerative | DRUG: Cefuroxime|DRUG: Ciprofloxacin|DRUG: Clarit… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Successful response of primary sclerosing cholangitis and associated ulcerative…
PMID: 33231850
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Primary sclerosing cholangitis (PSC) is a rare, progressive liver disease characterized by cholestasis and bile duct fibrosis that has no accepted th…
The role of oral vancomycin in inducing remission for biologic-experienced ulce…
PMID: 33130984
Year: 2021
Relationship Type:
Treatment
Score: 6.5
While a minority of patients with ulcerative colitis has primary sclerosing cholangitis (PSC), a significant proportion of patients with PSC have ulc…
The effect of immunoregulatory bacteria on the transcriptional activity of Foxp…
PMID: 32685120
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND OBJECTIVES: Intestinal microbiota is involved in the development and maintenance of immune homeostasis. This study was conducted to in…
Vancomycin loading dose is associated with increased early clinical response wi…
PMID: 32301537
Year: 2020
Relationship Type:
Treatment
Score: 6.5
WHAT IS KNOWN AND OBJECTIVE: Vancomycin therapeutic guidelines suggest a loading dose of 25-30 mg/kg for seriously ill patients. However, high-qualit…
Oral vancomycin induces sustained deep remission in adult patients with ulcerat…
PMID: 30052539
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology. The treatment of UC is challenging, especially when it is associ…
Fecal Microbiota Transplantation in Recurrent NAP1/B1/027 Clostridium Difficile…
PMID: 30044904
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Most of the studies showed that IBD patients inflammatory bowel diseases (IBD) with CDI have more of the whole range of short- and long-term worst ou…
Vancomycin pre-treatment impairs tissue healing in experimental colitis: Import…
PMID: 28034757
Year: 2017
Relationship Type:
Treatment
Score: 6.3
BACKGROUND AND AIMS: The interplay between luminal microbes and innate immunity during colonic epithelial repair has been well noted. At the same tim…
A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Chil…
PMID: 27877096
Year: 2016
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Oral vancomycin is used to treat refractory colitis due to Clostridium dificile infection. Traditionally, oral vancomycin was thought to …
Vancomycin-sensitive bacteria trigger development of colitis-associated colon c…
PMID: 27050089
Year: 2016
Relationship Type:
Treatment
Score: 6.3
Inflammatory bowel disease confers an increased risk of developing colitis-associated colon cancer (CAC). During the active colitis or developing tum…